elotuzumab

Ligand id: 8361

Name: elotuzumab

References
1. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y et al.. (2008)
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Clin. Cancer Res.14 (9): 2775-84. [PMID:18451245]
2. Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG et al.. (2008)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
Blood112 (4): 1329-37. [PMID:17906076]
3. van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R et al.. (2009)
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
Mol. Cancer Ther.8 (9): 2616-24. [PMID:19723891]
4. Veillette A, Guo H. (2013)
CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.
Crit. Rev. Oncol. Hematol.88 (1): 168-77. [PMID:23731618]
5. Williams M, Tso JY, Landolfi NF, Powers DB, Liu G. (2010)
Therapeutic use of anti-CS1 antibodies.
Patent number: US7709610. Assignee: Facet Biotech Corporation. Priority date: 28/05/2003. Publication date: 04/05/2010.